Physician profile
Shadi Bashour
NPI 1710298153
$3,936.67
in general payments reported to CMS, 2019-2025
32 companies · $895 in 2025
The $895 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $624 · 2021: $317 · 2022: $41.74 · 2023: $674 · 2024: $522 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,075 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.00 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $463.97 | 2019-2025 | Jynarque |
| Ardelyx, INC. | $391.28 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Vifor Pharma, INC. | $322.71 | 2019-2023 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $316.47 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $297.77 | 2019-2025 | Krystexxa |
| Travere Therapeutics, INC. | $229.68 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $211.91 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $174.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $170.15 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $161.44 | 2022-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $149.38 | 2020-2021 | |
| Akebia Therapeutics INC | $146.71 | 2019-2020 | |
| Horizon Therapeutics Plc | $139.82 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $116.85 | 2023-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $85.92 | 2023-2025 | Velphoro, Velphoro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $66.23 | 2023-2025 | |
| Daiichi Sankyo INC. | $54.23 | 2019-2021 | |
| Glaxosmithkline, LLC. | $51.67 | 2023 | Benlysta |
| Alnylam Pharmaceuticals INC. | $48.43 | 2023-2025 | Oxlumo, Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $48.17 | 2023 | Gattex |
| Xeris Pharmaceuticals, INC. | $37.31 | 2023-2024 | Keveyis |
| Genzyme Corporation | $34.52 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.17 | 2019 | |
| Pharmacosmos Therapeutics INC. | $34.06 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $26.00 | 2025 | Purified Cortrophin Gel |
| Cormedix INC. | $24.51 | 2024 | Defencath |
| Novo Nordisk INC | $21.60 | 2024 | Wegovy |
| Shire North American Group INC | $18.47 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.54 | 2025 | Empaveli |
| Lilly USA, LLC | $15.37 | 2023 | Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.05 | 2025 | Jardiance |
| Amag Pharmaceuticals, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Bashour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.